Analyst Ratings for [ALNY] Alnylam Pharmaceuticals, Inc.

11/12/24	Downgrades	Peer Perform Underperform	X
ALNY Alnylam Pharma Wolfe Research
10/16/24	Initiated	Sector Outperform	X
ALNY Alnylam Pharma Scotiabank
8/16/24	Upgrades	Neutral Buy	X
ALNY Alnylam Pharma Goldman
$198 $370
2/16/24	Downgrades	Buy Neutral	X
ALNY Alnylam Pharma Goldman
$173
2/15/24	Initiated	Peer Perform	X
ALNY Alnylam Pharma Wolfe Research
12/8/23	Initiated	Equal Weight	X
ALNY Alnylam Pharma Wells Fargo
$171
10/11/23	Downgrades	Outperform Perform	X
ALNY Alnylam Pharma Oppenheimer
9/29/23	Initiated	Outperform	X
ALNY Alnylam Pharma Raymond James
$208
5/5/23	Upgrades	Mkt Perform Outperform	X
ALNY Alnylam Pharma BMO Capital Markets
$200 $250
4/26/23	Initiated	Neutral	X
ALNY Alnylam Pharma SMBC Nikko
$220
3/21/23	Initiated	Outperform	X
ALNY Alnylam Pharma Bernstein
$243
1/18/23	Initiated	Buy	X
ALNY Alnylam Pharma Canaccord Genuity
$310
9/9/22	Resumed	Equal-Weight	X
ALNY Alnylam Pharma Morgan Stanley
$222
7/13/22	Initiated	Neutral	X
ALNY Alnylam Pharma Cantor Fitzgerald
$175
6/27/22	Downgrades	Buy Neutral	X
ALNY Alnylam Pharma Guggenheim
6/7/22	Initiated	Outperform	X
ALNY Alnylam Pharma William Blair
4/25/22	Downgrades	Overweight Eq-Weight	X
ALNY Alnylam Pharma Morgan Stanley
$210 $178
2/3/22	Upgrades	Neutral Buy	X
ALNY Alnylam Pharma Guggenheim
$170
1/3/22	Upgrades	Neutral Overweight	X
ALNY Alnylam Pharma Piper Sandler
$181 $208
11/22/21	Upgrades	Neutral Buy	X
ALNY Alnylam Pharma Goldman
$273
11/22/21	Upgrades	Sec Perform Outperform	X
ALNY Alnylam Pharma RBC Capital Mkts
$144 $225
11/1/21	Upgrades	Perform Outperform	X
ALNY Alnylam Pharma Oppenheimer
$200
10/4/21	Upgrades	Neutral Buy	X
ALNY Alnylam Pharma UBS
$141 $215
2/22/21	Downgrades	Buy Neutral	X
ALNY Alnylam Pharma Guggenheim
$162
2/12/21	Downgrades	Buy Neutral	X
ALNY Alnylam Pharma Citigroup
$170 $175
2/12/21	Reiterated	Buy	X
ALNY Alnylam Pharma H.C. Wainwright
$225 $235
1/25/21	Downgrades	Outperform Mkt Perform	X
ALNY Alnylam Pharma BMO Capital Markets
$185
5/23/19	Resumed	Neutral	X
ALNY Alnylam Pharma Goldman
$80
4/12/19	Initiated	Outperform	X
ALNY Alnylam Pharma Evercore ISI
3/5/19	Upgrades	Eq-Weight Overweight	X
ALNY Alnylam Pharma Morgan Stanley
1/23/19	Initiated	Neutral	X
ALNY Alnylam Pharma UBS
$87
10/1/18	Initiated	Overweight	X
ALNY Alnylam Pharma Cantor Fitzgerald
$135
8/13/18	Reiterated	Buy	X
ALNY Alnylam Pharma Stifel
$125 $123
8/7/18	Upgrades	Hold Buy	X
ALNY Alnylam Pharma Stifel
$95 $125
5/4/18	Reiterated	Hold	X
ALNY Alnylam Pharma Stifel
$107 $95
3/28/18	Initiated	In-line	X
ALNY Alnylam Pharma Evercore ISI
3/26/18	Reiterated	Mkt Outperform	X
ALNY Alnylam Pharma JMP Securities
$169 $207
2/16/18	Reiterated	Buy	X
ALNY Alnylam Pharma B. Riley FBR, Inc.
$205 $200

ALNY Alnylam Pharmaceuticals, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).